Lv2
180 积分 2023-02-17 加入
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
5天前
已完结
一项关于斯贝利单抗治疗IgA肾病的3期临床试验的中期分析
5天前
已完结
A study to compare the effectiveness and safety of Atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function
5天前
已关闭
Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial
5天前
已完结
Sibeprenlimab: First Approval
5天前
已完结
Efficacy and safety of agents for IgA nephropathy: a network meta-analysis of randomized controlled trials
1个月前
已完结
皖公网安备34019202002308
